

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

DUFT, Bradford J., *et al.*

Appln. No.: 09/445,517

Filed: June 5, 1998

For: *Methods for Treating Obesity*

Art Unit: 1654

Examiner: DEVI, Sarvamangala

Atty. Docket: 235/013US

Confirm. No.: 1018

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, Applicants bring to the Examiner's attention the references cited in the attached PTO/SB/08b Form and, with the exception of U.S. patents and U.S. patent application publications, a copy of each of the cited references is enclosed herewith. Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08A, indicating that the information has been considered and made of record herein.


This Information Disclosure Statement is being filed before the issuance of a first Office Action on the merits and before a Notice of Allowance. Accordingly, no fee is due. However, if a first Office Action on the merits has been mailed, then this Statement is filed under the provisions of 37 C.F.R. § 1.97(c)(2) with authorization to charge the fee under of 37 C.F.R. § 1.17(p) to Applicant's deposit account, provided below.

This Statement should not be construed as an admission that any information provided herewith is material as that term is defined in 37 C.F.R. § 1.56(b) or that any of the cited references qualifies as prior art. This Statement should not be construed as a representation that a search has been made, or that information or more material does not exist.

Applicants believe that neither a statement nor fee under 37 C.F.R. 1.97(c) is required in connection with this communication. If Applicants are mistaken, the Commissioner is herewith authorized to charge any fee due to Deposit Account No. 01-0535.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.



Timothy E. Torchia
Registration No. 36,700

Date: 12 March 2010

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Telephone: 858-552-2200
Direct Dial: 858-754-4153